





## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification <sup>6</sup> : C07D 495/04, A61K 31/505, 31/44 // (C07D 495/04, 333:00, 239:00) (C07D 495/04, 333:00, 221:00)</p>	<p>A1</p>	<p>(11) International Publication Number: <b>WO 99/24440</b></p> <p>(43) International Publication Date: 20 May 1999 (20.05.99)</p>
<p>(21) International Application Number: PCT/IB98/01691</p> <p>(22) International Filing Date: 22 October 1998 (22.10.98)</p> <p>(30) Priority Data: 60/065,097 11 November 1997 (11.11.97) US</p> <p>(71) Applicant (for all designated States except US): PFIZER PRODUCTS INC. [US/US]; Eastern Point Road, Groton, CT 06340 (US).</p> <p>(72) Inventors; and</p> <p>(75) Inventors/Applicants (for US only): MUNCHHOF, Michael, John [US/US]; 266 West Road, Salem, CT 06420 (US). SOBOLOV-JAYNES, Susan, Beth [US/US]; 4 Piney Branch Road, Ivoryton, CT 06442 (US).</p> <p>(74) Agents: SPIEGEL, Allen, J. et al.; Pfizer Inc., 235 East 42nd Street, New York, NY 10017 (US).</p>		<p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published With international search report.</p>
<p>(54) Title: THIENOPYRIMIDINE AND THIENOPYRIDINE DERIVATIVES USEFUL AS ANTICANCER AGENTS</p> <div style="display: flex; justify-content: space-around; align-items: center;"> <div style="text-align: center;">  <p>(1)</p> </div> <div style="text-align: center;">  <p>(2)</p> </div> </div> <p>(57) Abstract</p> <p>The invention relates to compounds of formulas (1) and (2) and to pharmaceutically acceptable salts and hydrates thereof, wherein X<sup>1</sup>, R<sup>1</sup>, R<sup>2</sup> and R<sup>11</sup> are as defined herein. The invention also relates to pharmaceutical compositions containing the compounds of formulas (1) and (2) and to methods of treating hyperproliferative disorders in a mammal by administering the compounds of formulas (1) and (2).</p>		